Companies

Request More Information

Last:
Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

Experts Commenting on This Company

 

Visit Company Website

View Company News



Amarantus BioScience Holdings Inc.

TICKER: AMBS:OTCQB

Amarantus BioScience Holdings Inc. is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, such as retinitis pigmentosa, Parkinson's disease, Alzheimer's disease, traumatic brain injury and other human diseases. The company has an exclusive worldwide license to the Lymphocyte Proliferation test for Alzheimer's disease, owns the intellectual property rights to the therapeutic protein mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for various protein folding-related medical conditions. Amarantus also owns intellectual property rights for the discovery of neurotrophic factors (PhenoGuard).


The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.

Expert Comments:

Mick Cooper, Edison Investment Research (8/18/14) "Commercial launch of Amarantus BioScience Holdings Inc.'s LymPro as a laboratory developed test remains on track for H2/14. The mesencephalic-astrocyte-derived neurotrophic factor has also started formal preclinical testing and could begin clinical development in 2015."

Jason Napodano, Seeking Alpha (8/6/14) "Last month Amarantus BioScience Holdings Inc. presented data on LymPro, the company's Alzheimer's disease blood test. . .a rapid and economical test like LymPro could be used to improve Alzheimer's patient enrollment for future clinical trials. . .we believe investor expectations on the data may have gotten out of line. . .when the analysis of blood samples using version 2 of the test is conducted, we expect the results will be superior to what was seen in July. . .the current goal is on obtaining CLIA approval before the end of the year. . .we believe today is an attractive entry opportunity."

Mick Cooper, Edison Investment Research (5/14/14) "Amarantus BioScience Holdings Inc. has a transformative year ahead and a diverse pipeline of promising products. Its diagnostic test for Alzheimer's disease (AD), LymPro, should be launched in H214. It will be the first blood-based test available for AD in the U.S., where there are about 0.5m people diagnosed with AD each year. Profits from LymPro could be used to develop eltoprazine and mesencephalic astrocyte-derived neurotrophic factor (MANF). . .MANF could start clinical development in 2015 and has potential in many indications."

Jason Napodano, Zacks Small-Cap Research (4/25/14) "On April 21, 2014, Amarantus Bioscience Holdings Inc. announced financial results for the year ended Dec. 31, 2013. Having spent much of the past year cleaning up the balance sheet, the company now has the financial resources to drive its assets forward in the clinic." -Zacks Small-Cap Research

The Life Sciences Report Interview with David Lowe (3/26/14) "Amarantus BioScience Holdings Ltd.'s eltoprazine molecule is now in Phase 2b for Parkinson's disease levodopa-induced dyskinesia (PD-LID), as well as attention-deficit hyperactivity disorder (ADHD). Amarantus CEO Gerald Commissiong led the charge on the negotiation front and did a brilliant job. . .

The company has been focusing on some orphan indications, such as retinitis pigmentosa (RP); it is in preclinical development with mesencephalic astrocyte-derived neurotrophic factor (MANF) in not only RP, an orphan indication, but also in Parkinson's, with some grant funding from the Michael J. Fox Foundation for Parkinson's Research. . .we believe this molecule, MANF, is one of the jewels in the field. . .we have one or two other indications for MANF, as well as the Amarantus' lead compound, eltoprazine, which is in the clinic. . . More >

more comments

Jason Napodano, Seeking Alpha (2/18/14) "Amarantus BioScience Holdings Inc. has entered into a definitive agreement with certain existing shareholders to exercise outstanding warrants that will deliver, at a minimum, $3M in new capital to the company. . .over the next few months, we expect Amarantus to put this new cash to work in several places."

Jason Napodano, Seeking Alpha (11/19/13) "We believe fundamentals are improving at Amarantus BioScience Holdings Inc., both with respect to the development of MANF (Mesencephalic-astrocyte-derived Neurotrophic Factor) and LymPro, and on the balance sheet. These improvements are the primary reasons why we believe investors should buy the stock today. . .right now the fundamentals are pointing to a potential breakout in 2014."

The Life Sciences Report Interview with Zack Lynch (10/17/13) "One interesting smaller company I can name is Amarantus BioScience Holdings Inc. It has acquired and is making progress on a very interesting diagnostic for Alzheimer's disease." More >

Jason Napodano, Zacks Small-Cap Research (10/14/13) "This morning, Amarantus BioSciences Holdings Inc. announced positive analytical performance data for the LymPro test, the company's flagship blood test for Alzheimer's disease. According to the company, the data produced begins the process necessary to establish long-term analytical performance to support commercial launch in H2/14, and allows Amarantus to start focusing on the clinical performance data package the company believes will be required for a successful product launch. . .we think the company's MANF (Mesencephalic-astrocyte-derived Neurotrophic Factor) is worth $40M. . .thus, we think Amarantus is worth $90M, and that represents over 200% upside from today."

fewer comments
Due to permission requirements, not all quotes are shown.

Amarantus BioScience Holdings Inc. Content



Back to Top